Abstract:e14026 Background: For patients with metastatic colorectal cancer, both FOLFOX regimen and FOLFIRI regimen are considered as first-line choices. However, only about half of patients could have an obvious response, and there are no clinically useful markers that could predict the response to these regimens respectively. A major clinical challenge is to identify the subset of patients who could benefit from those regimens. We aimed at identifying serum protein patterns which could predict the efficacy of chemotherapy. Methods: Serum from 70 patients diagnosed as metastatic colorectal cancer before first-line chemotherapy were collected and analyzed for protein patterns using artificial neural networks (ANN) analysis of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Among the 70 cases, 44 patients received FOLFOX chemotherapy, while the other 26 patients received FOLFIRI chemotherapy. After four cycles of the treatment, RECIST criteria were used to define the responders (R) and non-responders (NR). Results: With the method of SELDI-TOF-MS,a potential predicting pattern consisting of 6 biomarkers (9,298m/z, 9,282m/z, 4,606m/z, 9,198m/z, 7,775m/z and 2,266m/z) was identified in the patients receiving FOLFOX chemotherapy. Using this predicting pattern, the responders could be separated from the non-responders with a sensitivity of 92.9%, and a specificity of 81.3%. Another potential predicting pattern that consisted of 7 biomarkers (4,321m/z, 4,305m/z, 2,648m/z, 2,952m/z, 4,121m/z, 4,292m/z and 3,980 m/z) was identified in the patients who have received FOLFIRI chemotherapy. Using this predicting pattern, the responders could be separated from the non-responders with a sensitivity of 92.3% and a specificity of 92.3 %. Conclusions: Two potential patterns for the prediction of efficacy of FOLFOX or FOLFIRI chemotherapy were established in this preliminary study. These protein patterns could be helpful for oncologists to make a decision in selecting suitable first-line regimens for metastatic colorectal cancer patients.

[Analysis of Serum Protein Fingerprints on Non-Small Cell Lung Cancer Lymphatic Metastasis].

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

[Surface Enhanced Laser Desorption/ionization Time-of-flight Mass Spectrometry Profiling of Serum in Detection of Laryngeal Squamous Cell Carcinoma and the Progression to Lymph Node Metastasis].

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS

Detection and Significance of Serum Protein Markers of Small-Cell Lung Cancer

Research on the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer using SELDI-TOF-MS

[Serum Proteomic Patterns May Assist the Diagnosis of Solitary Pulmonary Nodules].

[Application of SELDI-TOF-MS in Detection of Liver Metastasis from Colorectal Cancer].

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy

Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifying biomarkers of laryngeal carcinoma

[Analysis of proteomic spectra in serum from patients with laryngeal carcinoma by SELDI-TOF-MS technology]

The study of lung adenocarcinoma serum biomarkers selected by surface-enhanced laser desorption ionization spectrometry

[Establishment of serum protein pattern model for screening pancreatic cancers by SELDI-TOF-MS technique]

Proteomic Patterns in Serum of Lung Adenocarcinoma Patients and Its Correlation with Clinical TNM Stage

Identification of Candidate Molecular Markers Predicting Chemotherapy Resistance in Non-Small Cell Lung Cancer

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Identification of the Biomarkers for the Prediction of Efficacy in the First-Line Chemotherapy of Metastatic Colorectal Cancer Patients Using SELDI-TOF-MS and Artificial Neural Networks.

[The contribution for the diagnosis of the tumor-like polypoid lesions of the gallbladder by SELDI-TOF-MS]